Product
SY-2101
Aliases
Oral Arsenic Trioxide, Oral ATO
1 clinical trial
1 indication
Indication
Acute Promyelocytic LeukemiaClinical trial
An Open-label Phase 1 Study to Evaluate Pharmacokinetics, Safety, and Tolerability of SY-2101 in Adult Patients With Acute Promyelocytic LeukemiaStatus: , Estimated PCD: 2024-01-03